Illumina Launches Protein Prep, Expanding Proteomic Research Horizons
Illumina, a leading genomics company, has expanded its portfolio with the commercial launch of Protein Prep in 2025. This innovative assay can measure up to 9,500 unique human protein targets using next-generation sequencing (NGS), with early access available since March 2024.
Protein Prep integrates seamlessly with Illumina's sequencing platforms and software tools, simplifying workflows from sample to analysis. This integration allows researchers to streamline their processes, saving time and resources.
The assay's ability to measure a vast number of protein targets opens up new possibilities in proteomic research. Protein Prep enables the integration of proteomic data into large-scale genomics studies, facilitating biomarker discovery and therapeutic development across various diseases.
Illumina's Protein Prep assay, launched in 2025, offers a powerful tool for proteomic research. By integrating proteomic data into genomics studies and measuring thousands of protein targets, Protein Prep promises to accelerate discoveries in biomarker identification and therapeutic development.
Read also:
- Trump and Xi speak over the phone, according to China's confirmation.
- Prices of transit tickets in Berlin and Brandenburg are on the rise
- Linde Wins Major Engineering Design Contract for Equinor's Low Carbon Hydrogen Project at H2H Saltend, Progressing Towards a Greener Future
- Economic Growth of Nitric Acid for Electronic Applications Anticipated to Reach 5.8% by 2034
